Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177140 | 0.90 | ACHE (0.38) | KMT2AMEN1POLBEPHX2TDP1 | |
| SCHEMBL22174786 | 0.83 | KMT2A (0.40) | KMT2AMEN1POLBEPHX2TDP1 | |
| SCHEMBL26793785 | 0.83 | KMT2A (0.40) | KMT2AMEN1POLBEPHX2TDP1 | |
| SCHEMBL10280126 | 0.83 | KMT2A (0.40) | KMT2AMEN1POLBEPHX2TDP1 | |
| SCHEMBL12228098 | 0.80 | TSHR (0.46) | KMT2AMEN1POLBTDP1TSHR | |
| SCHEMBL25854177 | 0.80 | TSHR (0.46) | KMT2AMEN1POLBTDP1TSHR | |
| SCHEMBL27429089 | 0.78 | MEN1 (0.31) | KMT2AMEN1POLB | |
| SCHEMBL8263008 | 0.77 | MEN1 (0.47) | KMT2AMEN1POLBEPHX2TDP1 | |
| SCHEMBL27429094 | 0.77 | SMYD3 (0.32) | ALDH1A1 | |
| SCHEMBL23187583 | 0.74 | CHRNA7 (0.33) | EPHX2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2017088738-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | 南京明德新药研发股份有限公司 | 2017-06-01 | — | — | WO | disclosed |
| US-8865753-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875640-B2 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TRPV1 | KMT2A 2433/4885MEN1 3535/4885POLB 4696/4885 |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | KMT2A 2410/4885MEN1 3076/4885POLB 4825/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | KMT2A 3944/4885MEN1 1965/4885POLB 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.